Legend Biotech Corp LEGN
Legend Biotech Corp (Nasdaq: LEGN) is an oncology drug developer. Its lead program, CARVYKTI (ciltacabtagene autoleucel, cilta-cel), is in Pre-clinical for relapsed/refractory multiple myeloma.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CARVYKTI (cilta-cel), co-developed/commercialized with Janssen | RRMM (4+ prior lines; 1+ prior line lenalidomide-refractory) | cell therapy | Approved |
| LB2501 (in vivo CD19/CD20 dual-targeting CAR-T) | relapsed/refractory B-cell non-Hodgkin lymphoma / B-cell malignancies | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.